SCHEMBL402080

SCHEMBL402080

COc1cc(C(=O)OCC(=O)N(C)C)cc(Cl)c1OC(=O)CCCc1ccc(NC(=O)c2ccc(C)nc2-c2ccc(C(F)(F)F)cc2)c(C(=O)N(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.38
NTRK2 Q16620 1/20 0.38
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PPARA Q07869 2/20 0.34
PPARG P37231 2/20 0.34
MAPT P10636 1/20 0.32
MTTP P55157 3/20 0.32
PDE5A O76074 2/20 0.32
KCNH2 Q12809 1/20 0.32
PDE6D O43924 1/20 0.32
PDE6A P16499 1/20 0.32
PDE6G P18545 1/20 0.32
PDE6B P35913 1/20 0.32
PDE6C P51160 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403076 0.96 NTRK1 (0.39) NTRK1NTRK2MEN1HPGDKMT2A
SCHEMBL397835 0.94 NTRK1 (0.39) NTRK1NTRK2MEN1KMT2ACYP1A2
SCHEMBL402301 0.93 NTRK1 (0.38) NTRK1NTRK2HPGDCYP1A2CYP3A4
SCHEMBL402008 0.92 NTRK1 (0.41) NTRK1NTRK2MEN1HPGDKMT2A
SCHEMBL401640 0.91 NTRK1 (0.36) NTRK1NTRK2CYP1A2CYP3A4CYP2C9
SCHEMBL399925 0.91 NTRK1 (0.36) NTRK1NTRK2HPGDCYP1A2CYP3A4
SCHEMBL402475 0.90 NTRK1 (0.37) NTRK1NTRK2MEN1HPGDKMT2A
SCHEMBL403797 0.90 NTRK1 (0.40) NTRK1NTRK2MEN1HPGDKMT2A
SCHEMBL400298 0.90 NTRK1 (0.41) NTRK1NTRK2MEN1KMT2ACYP1A2
SCHEMBL401877 0.89 NTRK1 (0.39) NTRK1NTRK2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP claimed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US claimed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA NTRK1 3420/4885NTRK2 2775/4885MEN1 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.